

# WALDER WYSS ADVISES CRISPR ON USD 600 MILLION SHARE SALE PROGRAM

*Posted on 1 February 2021*



**Category:** [Capital Markets](#)

**Tags:** [Alex Nikitine](#), [Christian Lütolf](#), [Ex-Featured](#), [Janine Corti](#), [Maurus Winzap](#), [Rafael Zemp](#)



In January 2021, CRISPR Therapeutics announced subsequent sales under the Open Market Sale Agreement with Jefferies LLC, under which CRISPR may offer and sell, from time to time at its sole discretion through Jefferies (as its sales agent), common shares having an aggregate offering price of up to USD 600 million. The sales will be made by any method that is deemed an “at the market offering” (ATM) under the US Securities Act. Together with the ATM-Program launched in 2020, the total volume has reached almost USD 1 billion.

CRISPR is a gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR is headquartered in Zug, Switzerland. CRISPR’s common shares are listed on the Nasdaq.

## The team

**Walder Wyss [has acted as Swiss counsel to CRISPR in connection with the transaction](#). The team is being led by Alex Nikitine (Partner, Corporate/M&A, Capital Markets - pictured) and further includes Rafael Zemp (Managing Associate, Corporate/M&A, Capital Markets), Christian Lütolf (Associate,**

**Corporate/M&A), Maurus Winzap (Partner, Tax) and Janine Corti (Counsel, Tax).**